Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease
NASDAQ,
-- Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to…